| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 08/19/2004 | WO2004060390A3 Use of a specific inhibitor of the 5ht2b receptor for the treatment of cancer |
| 08/19/2004 | WO2004054356A3 Transgenic animals produced using oral administration of a genetic agent coupled to a transporting agent |
| 08/19/2004 | WO2004050678A3 Compounds resistant to metabolic deactivation and methods of use |
| 08/19/2004 | WO2004043994A3 A retro-inverso gonadotropin-releasing hormone peptide and vaccine composition |
| 08/19/2004 | WO2004024076A9 Novel compositions and methods for the treatment of immune related diseases |
| 08/19/2004 | WO2004019912A3 Buccal, polar or non-polar spray or capsule containing drugs for treating an infectious disease or cancer |
| 08/19/2004 | WO2004010957B1 Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease |
| 08/19/2004 | WO2003092585A3 Controlled release compositions of estradiol metabolites |
| 08/19/2004 | WO2003077834A3 Central airway administration for systemic delivery of therapeutics |
| 08/19/2004 | WO2003072720A3 Recombinant parainfluenza virus expression systems and vaccines comprising heterologous antigens derived from metapneumovirus |
| 08/19/2004 | WO2003057134A8 Specific binding agents of human angiopoietin-2 |
| 08/19/2004 | WO2003053364A3 Methods and compositions in treating pain and painful disorders using 1465,1587, 2146, 2207, 32838, 336 and 52908 |
| 08/19/2004 | WO2003051886A8 Pyrazolopyridazine derivatives |
| 08/19/2004 | WO2003038123A3 Methods to treat diabetes and related conditions based on polymorphisms in the tcf1 gene |
| 08/19/2004 | WO2003025149A8 Cell populations which co-express cd49c and cd90 |
| 08/19/2004 | US20040162433 Lipoxin A4 analogs |
| 08/19/2004 | US20040162426 TNF (tumor necrosis factor); for treating conditions such as rheumatoid and osteoarthritis, corneal, epidermal or gastric ulceration; tumor metastasis or invasion; periodontal disease and bone disease |
| 08/19/2004 | US20040162354 Treatment of disease states which result from neoplastic cell proliferation using PPAR-gamma activators and compositions useful therefor |
| 08/19/2004 | US20040162353 Alpha-difluoromethylornithine(DFMO) suppresses polyamine levels in the human prostate |
| 08/19/2004 | US20040162329 Structural carotenoid analogs for the inhibition and amelioration of disease |
| 08/19/2004 | US20040162314 Enzyme inhibitors of phosphordiesterase 4 having minimal side effects; antiinflammatory agents; antiallergens; asthma; neurodegenerative disorders; antidiabetic agents; pain; anti-tumor, -carcinogenic and -arthritic agents |
| 08/19/2004 | US20040162304 Estrogen receptor modulators |
| 08/19/2004 | US20040162300 As inhibitor of tyrosine kinase enzymes, therapy of cancer |
| 08/19/2004 | US20040162291 For therapy of cardiovascular disorders and erectile dysfunction |
| 08/19/2004 | US20040162290 For therapy of cancer, benign prostatic hypertrophy or myoma of the uterus, endometriosis, polycystic ovarian disease, uterine fibroids or precocious puberty, lupus erythematosis, irritable bowel syndrome, premenstrual syndrome, hirsutism |
| 08/19/2004 | US20040162288 LPAAT-beta inhibitors and uses thereof |
| 08/19/2004 | US20040162276 Indazole or indole derivatives, and use thereof in human medicine and more particularly in oncology |
| 08/19/2004 | US20040162274 Inhibition of steroid synthesis by use of progesterone or a progesterone receptor agonist |
| 08/19/2004 | US20040162257 For inhibiting angiogenesis |
| 08/19/2004 | US20040161814 for drug screening enzyme inhibitors using gel chromatography; bioassays; gene therapy; genetic engineering |
| 08/19/2004 | US20040161806 Cells having transferred proteins, and methods of use thereof |
| 08/19/2004 | US20040161760 Using concentration of expression products from cell proliferation marker to diagnosis and prognose leukemic disorders; gene expression analysis and cancer disorders |
| 08/19/2004 | US20040161745 Nucleotide sequences coding glucuronidase for identifying modulators for treatment of inflammation; wound healing agents and tissue repair |
| 08/19/2004 | US20040161475 Anticancer, antitumor agents; ssynergistic mixtures with retinoic acid; olid tumors |
| 08/19/2004 | US20040161457 Method of administering a compound to multi-drug resistant cells |
| 08/19/2004 | US20040161456 Delivery and activation through liposome incorporation of diaminocyclohexane platinum(II) complexes |
| 08/19/2004 | US20040161430 Dye-azide compounds for dual phototherapy |
| 08/19/2004 | US20040161415 Inducted heat shock proteins in activated lymphocytes |
| 08/19/2004 | US20040161405 Guanidinium transport reagents and conjugates |
| 08/19/2004 | US20040160876 Method for determining a tilt angle of an optical pickup head |
| 08/19/2004 | DE10237722A1 Indol- oder Benzimidazolderivate zur Modulation der IKappaB-Kinase Indole or benzimidazole derivatives for the modulation of IkappaB kinase |
| 08/19/2004 | CA2515717A1 Melanin-concentrating hormone receptor antagonists containing piperidine derivatives as the active ingredient |
| 08/19/2004 | CA2515644A1 Oligomeric compounds for the modulation of ras expression |
| 08/19/2004 | CA2515623A1 Oligomeric compounds for the modulation of survivin expression |
| 08/19/2004 | CA2515335A1 Growth factor complexes and modulation of cell migration and growth |
| 08/19/2004 | CA2515331A1 Polymer guanidine derivatives as a cytostatic medicament |
| 08/19/2004 | CA2515302A1 Sensitizing cells for apoptosis by selectively blocking cytokines |
| 08/19/2004 | CA2515174A1 Breast cancer resistance protein (bcrp) inhibitor |
| 08/19/2004 | CA2515135A1 Breast cancer-resistant protein inhibitor |
| 08/19/2004 | CA2515123A1 Immunogenic cd91 ligand-antigenic molecule complexes and fusion proteins |
| 08/19/2004 | CA2515122A1 Immunogenic cd91 ligand-antigenic molecule complexes and fusion proteins |
| 08/19/2004 | CA2515100A1 Trimeric polypeptide construct to induce an enduring t cell response |
| 08/19/2004 | CA2515081A1 Amphiregulin antibodies and their use to treat cancer and psoriasis |
| 08/19/2004 | CA2514841A1 Cell-killing molecules and methods of use thereof |
| 08/19/2004 | CA2513631A1 Cyclic urea derivatives, preparation method thereof and pharmaceutical use of same as kinase inhibitors |
| 08/19/2004 | CA2513401A1 N-monoacylated o-phenylenediamines as anti -cancer agents |
| 08/19/2004 | CA2513059A1 Novel tricyclic azepine derivatives, method for production therof and pharmaceutical compositions comprising the same |
| 08/18/2004 | EP1447451A1 MAMMALIAN CELL-INFECTING VIRUS VECTOR ENCODING EPITOPE-BOUND-BETA2m AND UTILIZATION THEREOF |
| 08/18/2004 | EP1447405A1 Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors |
| 08/18/2004 | EP1447401A1 Piperidin-2-one derivative compounds and drugs containing these compounds as the active ingredient |
| 08/18/2004 | EP1447099A2 Antineoplastic polyethylene conjugates of cytostatic compounds and pharmaceuticals comprising same |
| 08/18/2004 | EP1447092A1 Methods of inducing antigen-specific t cells |
| 08/18/2004 | EP1447091A1 Novel method of inducing antigen-specific t cells |
| 08/18/2004 | EP1447084A1 Freeze-dried pharmaceutical preparation |
| 08/18/2004 | EP1446501A2 Methods for identification of cancer cell surface molecules and cancer specific promoters, and therapeutic uses thereof |
| 08/18/2004 | EP1446500A2 A method for regulating immune function in primates using the foxp3 protein |
| 08/18/2004 | EP1446487A1 Mammalian protein phosphatases |
| 08/18/2004 | EP1446479A1 Recombinant adenovirus with enhanced therapeutic effect and pharmaceutical composition comprising said recombinant adenovirus |
| 08/18/2004 | EP1446423A2 Formulations of lymphokines and method of use thereof for local or both local and systemic control of proliferative cell disorders |
| 08/18/2004 | EP1446419A2 Therapeutic polypeptides, nucleic acids encoding the same, and methods of use |
| 08/18/2004 | EP1446418A2 Integrin targeting compounds |
| 08/18/2004 | EP1446416A1 Tumor specific monoclonal antibodies |
| 08/18/2004 | EP1446412A2 Novel lna compositions and uses thereof |
| 08/18/2004 | EP1446405A2 Inhibitors of cyclin-dependent kinases, compositions and uses related thereto |
| 08/18/2004 | EP1446401A2 C-5 modified indazolylpyrrolotriazines |
| 08/18/2004 | EP1446399A1 Piperazine derivatives having sst1 antagonistic activity |
| 08/18/2004 | EP1446393A1 2-amino-thiazoline derivatives and their use as inhibitors of inducible no-synthase |
| 08/18/2004 | EP1446392A1 Oligopeptides and compositions containing them as cathepsin s inhibitors |
| 08/18/2004 | EP1446391A2 Preparation and use of carbohydrate-based ring structures with antimicrobial and cytostatic activity |
| 08/18/2004 | EP1446388A1 1,2,4-triazole derivatives containing a sulphamate group as aromatase inhibitors |
| 08/18/2004 | EP1446384A1 Polymorphous form of rimonabant, preparation method and pharmaceutical compositions containing same |
| 08/18/2004 | EP1446382A1 Anthranilic acid amides and their use as vegf receptor tyrosine kinase inhibitors |
| 08/18/2004 | EP1446381A1 Anthranilic acid amides and pharmaceutical use thereof |
| 08/18/2004 | EP1446162A2 Combination motif immune stimulatory oligonucleotides with improved activity |
| 08/18/2004 | EP1446159A2 Immunotherapy for reversing immune suppression |
| 08/18/2004 | EP1446142A1 Potentiating the therapeutic effects of interferons |
| 08/18/2004 | EP1446136A2 Curcuminoid compositions exhibiting synergistic inhibition of the expression and/or activity of cyclooxygenase-2 |
| 08/18/2004 | EP1446124A1 Combination therapy comprising zd6474 and a taxane |
| 08/18/2004 | EP1446117A2 Treatment of acute myeloid leukemia with indolinone compounds |
| 08/18/2004 | EP1446116A1 Inhibitors of dipeptidyl peptidase iv |
| 08/18/2004 | EP1446115A2 Cyanoalkylamino derivatives as protease inhibitors |
| 08/18/2004 | EP1446110A2 Organosulfur inhibitors of tyrosine phosphatases |
| 08/18/2004 | EP1446106A2 Optimal polymer mixtures for gastric retentive tablets |
| 08/18/2004 | EP1446104A1 Spray drying methods and compositions thereof |
| 08/18/2004 | EP1446088A2 Intraorally disintegrating valdecoxib compositions prepared by fluid bed granulation process |
| 08/18/2004 | EP1446012A1 Combination bacteriolytic therapy for the treatment of tumors |
| 08/18/2004 | EP1446008A2 Compositions and methods for controlled release |
| 08/18/2004 | EP1345951B1 A substance or composition for the treatment of cancer |
| 08/18/2004 | EP1343434A4 Methods for contemporaneous administration of levamisole and 5-fluorouracil |
| 08/18/2004 | EP1324809A4 Process for selectively extracting bioactive components |